Heart Failure Drug Development Over the Eras
Year: 2024
Type: review
Abstract: Over the past decade, the field of heart failure (HF) has witnessed remarkable progress in drug development, resulting in the approval of numerous groundbreaking drugs by the U.S. Food and Drug Administration. To address some of these challenges, the U.S. Food and Drug Administration has issued guidance documents that have been critical in contemporary HF drug development; however, there are still many challenges in need of investigation. This paper leverages efforts of the Heart Failure Collaboratory and the scientific community to discuss the critical need for innovative trial designs, important concepts in clinical trials in the modern era, and the utilization of big data to accelerate HF drug development. At this inflection point in HF drug development, it is imperative that, as a global scientific community, we foster increased collaboration among researchers, clinicians, patients, and regulatory bodies. Only through such unified efforts can we navigate the complexities of HF, accelerate the development process, and ultimately deliver effective therapies that transform patient outcomes.
Source: JACC Heart Failure
Institutions: Inova Health System, Massachusetts General Hospital, Baim Institute for Clinical Research, Vanderbilt University Medical Center, Brigham and Women's Hospital, Harvard University, University of Colorado Anschutz, The Ohio State University Wexner Medical Center, The Ohio State University, United States Food and Drug Administration, Center for Drug Evaluation and Research, Duke Medical Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,750
OpenAlex ID: W4400486473